التفاصيل البيبلوغرافية
| العنوان: |
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. |
| المؤلفون: |
Donato, Eva M, Fernández-Zarzoso, Miguel, Hueso, Jose Antonio, de la Rubia, Javier |
| المصدر: |
OncoTargets & Therapy. Aug2018, Vol. 11, p4583-4590. 8p. |
| مصطلحات موضوعية: |
*HODGKIN'S disease, *ANAPLASTIC thyroid cancer, *LYMPHOMAS, *CANCER chemotherapy, *IMMUNOGLOBULINS |
| مستخلص: |
Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder